Boston Scientific Corp
- Branche
- Medical Devices
- Börse
- USA
- Land / Region
- USA
- Börsengang
- 18. Mai 1992
- Mitarbeiter
- 59.000
- Website
- www.bostonscientific.com
Zusammengesetzter Bewertungsbereich · konservativ $31–$40 / fair $50–$65 / optimistisch $80–$95. Bei $45.51, Zwischen dem konservativen und dem fairen Bereich.
Bei Veröffentlichung $57.78 (24. Mai 2026)
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Geschichte
Boston Scientific Corporation was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. It completed its IPO on May 18, 1992. The company has grown substantially through acquisitions: in 2024 it acquired Axonics and Silk Road Medical for about USD 4.64 billion, and in 2025 it paid about USD 1.593 billion for Bolt, SoniVie, Cortex, Intera and Anrei. In May 2026 it launched a USD 2 billion accelerated share repurchase, with initial pricing referencing the May 15, 2026 closing price of USD 52.68, and a larger Penumbra acquisition with an enterprise value of about USD 14.5 billion (roughly 73% cash, 27% stock) remained pending in 2026.
Branchenposition
Boston Scientific is a global medical device company operating in two reporting segments, MedSurg and Cardiovascular, and selling across 127 countries with about 59,000 employees, roughly 60% of whom are outside the United States. In 2025 revenue was USD 20.074 billion, with Cardiovascular contributing USD 13.250 billion and MedSurg USD 6.824 billion. The company holds strong positions in several device niches: WATCHMAN had cumulatively treated over 500,000 patients per its 2024 annual report, and its FARAPULSE PFA system had also treated over 500,000 patients per the 2025 report. In electrophysiology it faces stronger competition from Medtronic, Johnson & Johnson and Abbott, and no single customer accounts for more than 10% of revenue.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.